VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany's Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The company said the regulatory feedback provides greater clarity on its proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development.
VERAXA also highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 showing its lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets while sparing cells expressing only one target. According to the company, the studies demonstrated a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index.
For more details, the full press release is available at https://ibn.fm/jpXam. VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA. This announcement is significant as it marks a key regulatory milestone for VERAXA's BiTAC-TCE platform, potentially leading to a novel cancer therapy with improved safety and efficacy compared to traditional T-cell engagers. The regulatory feedback from the Paul-Ehrlich-Institute provides a clearer path forward for clinical development, which could benefit patients with cancers that are difficult to treat.
